Genetic determinants of treatment benefit of the angiotensin-converting enzyme-inhibitor perindopril in patients with stable coronary artery disease

European Heart Journal

Volumn 31, Issue 15, 2010, Pages 1854-1864

  Brugts, Jasper Jan ^a   Isaacs, Aaron ^a   Boersma, Eric ^a   Van Duijn, Cock M ^a   Uitterlinden, Andre G ^a   Remme, Willem ^b   Bertrand, Michel ^c   Ninomiya, Toshiharu ^d   Ceconi, Claudio ^e   Chalmers, John ^d   MacMahon, Stephen ^d   Fox, Kim ^f   Ferrari, Roberto ^e   Witteman, Jacqueline C M ^a   Danser, A H Jan ^a   Simoons, Maarten L ^a   De Maat, Moniek P M ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b Sticares Cardiovascular Research Foundation   (Netherlands)

^c Lille Heart Institute   (France)

^d ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^e UNIVERSITY OF FERRARA   (Italy)

^f NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

ACE inhibitors; Coronary artery disease; Gene; Individualized therapy; PERGENE; Perindopril; Pharmacogenetics; RAAS

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; BRADYKININ B1 RECEPTOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; INDAPAMIDE; PERINDOPRIL; PLACEBO;

ADULT; ARTICLE; CAUCASIAN; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG EFFICACY; FEMALE; FOLLOW UP; GENOTYPE; HEART ARREST; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PHARMACOGENETICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK REDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; STATISTICAL ANALYSIS;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CORONARY ARTERY DISEASE; FEMALE; GENE FREQUENCY; GENOTYPE; HEART ARREST; HUMANS; KALLIKREIN-KININ SYSTEM; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PERINDOPRIL; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTOR, BRADYKININ B1; RENIN-ANGIOTENSIN SYSTEM;

EID: 77955457212     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehq169     Document Type: Article

References (40)

1. Dagenais GR, Pogue J, Fox K, Simoons ML, Yusuf S. Angiotensin-converting- enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials. Lancet 2006;368:581-588.
2. The European trial on reduction of cardiac events with perindopril in patients with stable coronary artery disease investigators. Efficacy of perindopril in reduction of cardiovascular events in stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003;362:782-788.
3. The Heart Outcomes Prevention Evaluation study investigators. Effects of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000;342:145-153.
4. The PEACE Trial Investigators. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med 2004;351:2058-2068.
5. The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. Guidelines on the management of stable angina pectoris. Eur Heart J 2006;27:1341-1381.
6. Gibbons RJ, Abrams J, Chatterjee K, Daley J, Deedwania PC, Douglas JS, Ferguson TB Jr, Fihn SD, Fraker TD Jr, Gardin JM, O'Rourke RA, Pasternak RC, Williams SV, American College of Cardiology; American Heart Association Task Force on practice guidelines (Committee on the Management of Patients With Chronic Stable Angina). ACC/AHA 2002 guideline update for the management of patients with chronic stable angina\summary article: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Committee on the Management of Patients With Chronic Stable Angina). J Am Coll Cardiol 2003;41:159-168. (Pubitemid 36044419)
7. Deckers JW, Goedhart DM, Boersma E, Briggs A, Bertrand M, Ferrari R, Remme WJ, Fox K, Simoons ML. Treatment benefit by perindopril in patients with stable coronary artery disease at different levels of risk. Eur Heart J 2006; 27:796-801.
8. Brugts JJ, Boersma E, Chonchol M, Deckers JW, Bertrand M, Remme WJ, Ferrari R, Fox K, Simoons ML. The cardioprotective effects of the angiotensin-converting enzyme inhibitor perindopril in patients with stable coronary artery disease are not modified by mild to moderate renal insufficiency: insights from the EUROPA trial. J Am Coll Cardiol 2007;50:2148-2155.
9. Remme WJ, Deckers JW, Fox KM, Ferrari R, Bertrand M, Simoons ML, EUROPA Investigators. Secondary prevention of coronary disease with ACE inhibition\does blood pressure reduction with perindopril explain the benefits in EUROPA? Cardiovasc Drugs Ther 2009;23:161-170.
10. Brugts JJ, Ninomiya T, Boersma E, Remme WJ, Bertrand M, Ferrari R, Fox K, MacMahon S, Chalmers J, Simoons ML. The consistency of the treatment effect of an ACE-inhibitor based treatment regimen in patients with vascular disease or high risk of vascular disease: a combined analysis of individual data of ADVANCE, EUROPA, and PROGRESS trials. Eur Heart J 2009;30:1385-1394.
11. Danser AHJ, Schunkert H. Renin-angiotensin system gene polymorphisms: potential mechanisms for their association with cardiovascular diseases. Eur J Pharmacol 2000;410:303-316.
12. Brugts JJ, den Uil CA, de Maat M, Danser AHJ. The renin-angiotensin- aldoster-one system: approaches to guide angiotensin-converting enzyme inhibition in patients with coronary artery disease. Cardiology 2008;112:303-312.
13. Gainer JV, Morrow JD, Loveland A, King DJ, Brown NJ. Effect of bradykinin-receptor blockade on the response to angiotensin-converting-enzyme inhibitor in normotensive and hypertensive subjects. N Engl J Med 1998;339:1285-1292.
14. Gomma AH, Fox KM, for the EUROPA investigators. The EUROPA trial: design, baseline demography and status of the substudies. Cardiovasc Drugs Ther 2001;15: 169-179.
15. Brugts JJ, de Maat MPM, Boersma E, Witteman JCM, van Duijn C, Uitterlinden AG, Bertrand M, Remme W, Fox K, Ferrrari R, Danser AHJ, Simoons ML. The rationale and design of the perindopril genetic association study: a pharmacogenetic analysis of ACE-inhibitor therapy in patients with stable coronary artery disease. Cardiovasc Drugs Ther 2009;23:171-181.
16. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet 2001;358:1033-1041.
17. Nederhand RJ, Droog S, Kluft C, Simoons ML, de Maat MP. Logistics and quality control for DNA sampling in large multi-center studies. J Thromb Haemost 2003;1: 987-991.
18. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005; PMID:15297300
19. de Bakker PIW, Yelensky R, Pe'er I, Gabriel SB, Daly MJ, Altshuler D. Efficiency and power in genetic association studies. Nat Genet 2005;37:1217-1223.
20. Churchill GA, Doerge RW. Empirical threshold values for quantitative trait mapping. Genetics 1994;138:963-971.
21. Schaid DJ, Rowland CM, Tines DE, Jacobson RM, Poland GA. Score tests for association between traits and haplotypes when linkage phase is ambiguous. Am J Hum Genet 2002;70:425-434.
22. Kavvoura FK, Ioannidis JP. Methods for meta-analysis in genetic association studies: a review of their potential and pitfalls. Hum Genet 2008;123:1-14.
23. Trikalins TA, Salanti G, Zintzaras E, Ioannidis JP. Meta-analysis methods. Adv Genet 2008;60:311-334.
24. Simon T, Verstuyft C, Mary-Kraue M, Quteineh L, Drouet E, Meneveau N, Steg PG, Ferrieres J, Danchin N, Becquemont L, for the FAST-MI Investigators. Genetic Determinants of Response to Clopidogrel and Cardiovascular Events. New Engl J Med 2009;360:363-375.
25. The SEARCH collaborative group. SLCO1B1 variants and statin-induced myopa-thy, a genome wide study. N Engl J Med 2008;359:789-799.
26. International Warfarin Pharmacogenetics Consortium, Klein TE, Altman RB, Eriksson N, Gage BF, Kimmel SE, Lee MT, Limdi NA, Page D, Roden DM, Wagner MJ, Caldwell MD, Johnson JA.Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med 2009;360:753-764.
27. Brugts JJ, de Maat M, den Uil CA, Danser AHJ, Ferrari R, Simoons ML. Pharmaco-genetics of ACE inhibition in stable coronary artery disease: steps towards tailored drug therapy. Curr Opin Cardiol 2008;23:296-301.
28. Danser AH, Batenburg WW, van den Meiracker AH, Danilov SM. ACE phenotyp-ing as a first step toward personalized medicine for ACE inhibitors. Why does ACE genotyping not predict the therapeutic efficacy of ACE inhibition? Pharmacol Ther 2007;113:607-618.
29. PROGRESS Collaborative Group. The ACE gene I/D polymorphism is not associated with the blood pressure and cardiovascular benefits of ACE inhibition. Hypertension 2003;42:297-303.
30. Arnett DK, Davis BR, Ford CE, Boerwinkle E, Leiendecker-Foster C, Miller MB, Black H, Eckfeldt JH. Pharmacogenetic association of the angiotensin-converting enzyme insertion/deletion polymorphism on blood pressure and cardiovascular risk in relation to antihypertensive treatment: the Genetics of Hypertension-Associated Treatment (GenHAT) study. Circulation 2005;111:3374-3383.
31. Abdollahi MR, Huang S, Rodriguez S, Guthrie PA, Smith GD, Ebrahim S, Lawlor DA, Day IN, Gaunt TR. Homogeneous assay of rs4343, an ACE I/D proxy, and an analysis in the British Women's Heart and Health Study (BWHHS). Dis Markers 2008;24:11-17.
32. Gainer JV, Morrow JD, Loveland A, King DJ, Brown NJ. Effect of bradykinin-receptor blockade on the response to angiotensin converting-enzyme inhibitor in normotensive and hypertensive subjects. N Engl J Med 1998;339: 1285-1292.
33. Xu J, Carretero OA, Shesely EG, Rhaleb NE, Yang JJ, Bader M, Yang XP. The Kinin B1 Receptor Contributes to the Cardioprotective Effect of ACE Inhibitors and Angiotensin Receptor Blockers. Exp Physiol 2009;94:322-329.
34. Marin-Castaño ME, Schanstra JP, Neau E, Praddaude F, Pecher C, Ader JL, Girolami JP, Bascands JL. Induction of functional bradykinin b(1)-receptors in normotensive rats and mice under chronic Angiotensin-converting enzyme inhibitor treatment. Circulation 2002;5:627-632.
35. Ignatovic T, Tan F, Brovkovych V, Skidgel RA, Erdos GE. Novel Mode of Action of Angiotensin I Converting Enzyme Inhibitors: Direct activation of the Bradykinin Receptor type I. J Biol Chem 2002;277:16847-16852.
36. Ignjatovic T, Stanisavljevic S, Brovkovych V, Skidgel RA, Erdos EG, Kinin BI. Receptors stimulate nitric oxide production in endothelial cells: signaling pathways activated by angiotensin I-converting enzyme inhibitors and peptide ligands. Mol Pharmacol 2004;66:1310-1316.
37. Forten JP, Gobeil F Jr, Adam A, Regoli D, Marceau F. Do angiotensin-converting enzyme inhibitors directly stimulate the kinin B1 receptor? Am J Physiol Heart Circ Physiol 2003;285:H277-H282.
38. 1 receptors induces vasodila-tion in conductance and resistance coronary vessels in conscious dogs. Circulation 2000;101:1848-1853.
39. Austinat M, Braeuninger S, Pesquero JB, Brede M, Bader M, Stoll G, Renné T, Kleinschnitz C. Blockade of bradykinin receptor B1 but not bradykinin receptor B2 provides protection from cerebral infarction and brain edema. Stroke 2009; 40:285-293.
40. Ferrari R. Angiotensin-converting enzyme inhibition in cardiovascular disease: evidence with perindopril. Expert Rev Cardiovasc Ther 2005;3:15-29.